• Home
  • Infigratinib 25mg
  • Infigratinib 25mg

Infigratinib 25mg

52244

Infigratinib was previously used for adults with previously treated, unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, but its US approval was withdrawn in 2024, so current use depends on local approval.

Usual adult dose where still used under specialist direction: 125mg once daily for 21 days of each 28-day cycle, with lower doses used if side effects occur; local approval status should be checked.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.